Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Using knockout and transgenic technology, genetically modified animal models allowed us to understand the role of glucagon signalling in metabolism. Mice with a global deletion of the glucagon receptor gene (Gcgr) were designed using gene targeting. The phenotype of Gcgr −/− mouse provided important clues about the role of Gcgr in foetal growth, pancreatic development and glucose and lipid homeostasis. The lack of Gcgr activation was associated with: (i) hypoglycaemic pregnancies, poor foetal growth and increased foetal–neonatal demise; (ii) altered cytoarchitecture of pancreatic islets; (iii) altered glucose, lipid and hormonal milieu; (iv) reduced gastric emptying; (v) altered body composition and protection from diet‐induced obesity; (vi) altered energy state; (vii) impaired hepatocyte survival; (viii) altered metabolic response to prolonged fasting and exercise and (ix) prevented development of diabetes in insulin‐deficient mice. In contrast, mice overexpressing the Gcgr on pancreatic β ‐cells displayed an increase insulin secretion, pancreatic insulin content and β ‐cell mass, and partially protected against hyperglycaemia and impaired glucose tolerance when fed a high‐fat diet. These findings suggest that glucagon signalling plays a significant role in the regulation of glucose and lipid homeostasis. Treatment options designed to block Gcgr activation may have negative implications in the treatment of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ohtsubo, K., Takamatsu, S., Minowa, M. T., Yoshida, A., Takeuchi, M., & Marth, J. D. (2005) · Cell · doi:10.1016/j.cell.2005.09.041 · Cited by 429
Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327
Self-citationThe Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting
Longuet, C., Sinclair, E. M., Maida, A., Baggio, L. L., Maziarz, M., Charron, M. J., & Drucker, D. J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.008 · Cited by 272 · cited 3×
“Glucagon has potent hypolipaemic actions and reduces triglyceride (TG) and very low-density lipoprotein release as well as the deposition of triacylglycerol in the liver, in addition to reducing cholesterol levels and stimulating fatty acid oxidation [23,24].”
BackgroundSelf-citationConarello, S. L., Jiang, G., Mu, J., Li, Z., Woods, J., Zycband, E., Ronan, J., Liu, F., Roy, R. S., Zhu, L., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0481-3 · Cited by 224
Self-citationObesity, diabetes and the central nervous system
Porte Jr., D., Seeley, R. J., Woods, S. C., Baskin, D. G., Figlewicz, D. P., & Schwartz, M. W. (1998) · Diabetologia · doi:10.1007/s001250051002 · Cited by 186 · cited 1×
“Glucagon also elicits significant extrahepatic effects in tissues such as kidney, heart, adipose tissue, gastrointestinal tract, thyroid and central nervous system [1,2,16,22] (figure 1).”
BackgroundParadoxical Stimulation of Glucagon Secretion by High Glucose Concentrations
Salehi, A., Vieira, E., & Gylfe, E. (2006) · Diabetes · doi:10.2337/db06-0080 · Cited by 159 · cited 1×
“Glucagon secretion is stimulated by hypoglycaemia, arginine, gastric inhibitor polypeptide, gastrin and potassium chloride and inhibited by hyperglycaemia, insulin, zinc, GLP-1 (glucagon-like peptide 1) and somatostatin [4–12].”
BackgroundGlucagon is a primary controller of hepatic glycogenolysis and gluconeogenesis during muscular work
Wasserman, D. H., Spalding, J. A., Lacy, D. B., Colburn, C. A., Goldstein, R. E., & Cherrington, A. D. (1989) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1989.257.1.e108 · Cited by 155
Høy, M., Olsen, H. L., Bokvist, K., Buschard, K., Barg, S., Rorsman, P., & Gromada, J. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.00109.x · Cited by 32 · cited 1×
“Glucagon secretion is stimulated by hypoglycaemia, arginine, gastric inhibitor polypeptide, gastrin and potassium chloride and inhibited by hyperglycaemia, insulin, zinc, GLP-1 (glucagon-like peptide 1) and somatostatin [4–12].”
Background
Cited by
Brereton, M. F., Vergari, E., Zhang, Q., & Clark, A. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415583535 · Cited by 206
“In addition, glucagon is an important regulator of lipid metabolism, reducing plasma triglycerides and stimulating hepatic fatty acid oxidation (Longuet et al. 2008; Vuguin and Charron 2011).”
BackgroundKelly, R. P., Garhyan, P., Raddad, E., Fu, H., Lim, C. N., Prince, M. J., Pinaire, J. A., Loh, M. T., & Deeg, M. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12446 · Cited by 110
“Animal studies have shown that the absence [10,11] or blockade [11–17] of glucagon signalling reduces hepatic glucose production, improves glucose tolerance and ameliorates hyperglycaemia.”
BackgroundGlucagon receptor antagonism induces increased cholesterol absorption
Guan, H.-P., Yang, X., Lu, K., Wang, S.-P., Castro-Perez, J. M., Previs, S., Wright, M., Shah, V., Herath, K., Xie, D., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m060897 · Cited by 76
Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist
Damond, N., Thorel, F., Moyers, J. S., Charron, M. J., Vuguin, P. M., Powers, A. C., & Herrera, P. L. (2016) · eLife · doi:10.7554/elife.13828 · Cited by 74
“The extent of these benefits remains however disputed in situations where the b-cell population is nearly completely depleted, as in long-standing type 1 diabetes (Wang et al., 2012; Meier et al., 2005).”
Self-citation
Metadata
- Authors
- Vuguin, P. M., & Charron, M. J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-08-08
- Volume
- 13
- Issue
- s1
- Pages
- 144-150
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2023595800
- Cited by
- 47
- References
- 8
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01447.x
- The paper
- Vuguin, P. M., & Charron, M. J. (2011). Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01447.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.